| Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. | |
| | |
MedLine Citation:
|
PMID: 17584569 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: It is not known whether there exists a sex-dependent difference in the clinical benefit of abciximab in patients with acute coronary syndromes (ACS) undergoing a percutaneous coronary intervention (PCI). METHODS: We performed this retrospective analysis of 2022 patients (498 women) with ACS enrolled in the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial and randomized to receive abciximab or placebo during a PCI procedure. The incidence of major adverse cardiac events (MACE) during the 30 days after PCI was the primary end point of the study. RESULTS: Among men, the 30-day incidence of MACE was 8.6% in the abciximab group compared with 12.6% in the placebo group, relative risk (RR) 0.69 (95% confidence interval [CI] 0.50-0.94), P = .01. The 30-day incidence of MACE in women was 9.7% in the abciximab group compared with 9.9% in the placebo group, RR 0.98 (95% CI, 0.56-1.72), P = .97. After adjustment for baseline clinical and angiographic characteristics, there was no significant interaction between sex and abciximab (P = .71); adjusted RR was 0.70 (95% CI, 0.34-1.34) in women and 0.60 (95% CI, 0.40-0.90) in men. The incidence of major bleeding was significantly greater in women (3.6%) than in men (0.7%), RR 5.5 (95% CI, 2.54-11.9), P < .001, without any dependence on the form of therapy received. CONCLUSIONS: In patients with non-ST elevation ACS undergoing a PCI, the benefit with abciximab is greater in men than in women. This is apparently the result of sex-based differences in risk profile. |
| | |
Authors:
|
Julinda Mehilli; Gjin Ndrepepa; Adnan Kastrati; Franz-Josef Neumann; Jurriën ten Berg; Olga Bruskina; Franz Dotzer; Melchior Seyfarth; Jürgen Pache; Sebastian Kufner; Josef Dirschinger; Peter B Berger; Albert Schömig |
Related Documents
:
|
16503839 - Does occupational gender segregation influence the association of effort-reward imbalan... 12505219 - Gender-related changes in the practice and outcomes of percutaneous coronary interventi... 9420809 - Sex specific issues relating to nuclear cardiology. 18281809 - Sex-related differences in the angiographic results of 14,500 cases referred for suspec... 7916229 - Acute myocardial infarction in women: survival analysis in first six months. 3155449 - Sex differences in early and long-term results of coronary angioplasty in the nhlbi ptc... 11708709 - Nutrition practices and knowledge of college varsity athletes: a follow-up. 6419839 - Pigmentation and skin reaction to sun as risk factors for cutaneous melanoma: western c... 11035909 - Lower peak bone mass and its decline. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: American heart journal Volume: 154 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2007 Jul |
Date Detail:
|
Created Date: 2007-06-22 Completed Date: 2007-07-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 158.e1-7 Citation Subset: AIM; IM |
Affiliation:
|
Deutsches Herzzentrum Technische Universität, Munich, Germany. mehilli@dhm.mhn.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty, Transluminal, Percutaneous Coronary* Antibodies, Monoclonal / adverse effects*, therapeutic use Anticoagulants / adverse effects*, therapeutic use Coronary Disease / therapy* Female Follow-Up Studies Humans Immunoglobulin Fab Fragments / adverse effects*, therapeutic use Male Myocardial Infarction / epidemiology, etiology Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors* Postoperative Hemorrhage / chemically induced*, epidemiology* Retrospective Studies Sex Distribution Sex Factors Stents Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Immunoglobulin Fab Fragments; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 143653-53-6/abciximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Does coronary angioplasty after timely thrombolysis improve microvascular perfusion and left ventric...
Next Document: Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary int...